Cue Biopharma (CUE) Earnings Date, Estimates & Call Transcripts $0.83 +0.02 (+2.29%) Closing price 04:00 PM EasternExtended Trading$0.83 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cue Biopharma Earnings Summary Cue Biopharma announced Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.09, which beat analysts' consensus estimates of -$0.13 by $0.04. Quarterly revenue was reported to be $2.95 million, above analyst estimates of $2 million. With a trailing EPS of -$0.56, Cue Biopharma's earnings are expected to grow next year, from ($0.76) to ($0.55) per share. Latest Q2 Earnings DateAug. 12EstimatedConsensus EPS (Aug. 12) -$0.13 Actual EPS (Aug. 12) -$0.09 Beat By $0.04 Actual Revenue (Aug. 12) $2.95MQ2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Cue Biopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cue Biopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCUE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CUE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cue Biopharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($0.76) EPSNext Year EPS Consensus Estimate ($0.55) EPS Cue Biopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025-$0.13-$0.09+$0.04-$0.09$2.00M$2.95M5/12/2025Q1 2025-$0.14-$0.17 -$0.03-$0.17$0.90M$0.42M3/28/2025Q4 2024-$0.14-$0.13+$0.01-$0.13$1.70M$1.80M8/14/2024Q2 2024-$0.29-$0.20+$0.09-$0.20$1.12M$2.66M5/9/2024Q1 2024-$0.30-$0.25+$0.05-$0.25$0.73M$1.72M4/8/2024Q4 2023--$0.28--$0.28-$1.82M11/9/2023Q3 2023-$0.30-$0.24+$0.06-$0.24$1.49M$2.10M Cue Biopharma Earnings - Frequently Asked Questions When did Cue Biopharma announce their last quarterly earnings? Cue Biopharma (NASDAQ:CUE) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on CUE's earnings history. Did Cue Biopharma beat their earnings estimates last quarter? In the previous quarter, Cue Biopharma (NASDAQ:CUE) reported ($0.09) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.13) by $0.04. Learn more on analysts' earnings estimate vs. CUE's actual earnings. How much revenue does Cue Biopharma generate each year? Cue Biopharma (NASDAQ:CUE) has a recorded annual revenue of $8.29 million. How much profit does Cue Biopharma generate each year? Cue Biopharma (NASDAQ:CUE) has a recorded net income of -$40.67 million. CUE has generated -$0.56 earnings per share over the last four quarters. What is Cue Biopharma's EPS forecast for next year? Cue Biopharma's earnings are expected to grow from ($0.76) per share to ($0.55) per share in the next year. More Earnings Resources from MarketBeat Related Companies TKNO Earnings Results SCPH Earnings Results ALLO Earnings Results SGMT Earnings Results SOPH Earnings Results AARD Earnings Results FENC Earnings Results GALT Earnings Results ALEC Earnings Results TVRD Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings Report This page (NASDAQ:CUE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access